全球抗體生產市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計抗體生產市場將從 2025 年的 259.8 億美元成長到 2034 年的 533 億美元，2026 年至 2034 年的複合年成長率為 8.31%。

全球抗體生產市場正經歷顯著成長，這主要得益於腫瘤、自體免疫疾病和感染疾病領域單株抗體開發平臺的擴張。監管核准的增加和生物相似藥研發的進展正在加速生產需求。生物製藥設施的擴建以及外包給合約研發生產機構（CDMO）的增加，正在支持生產規模的擴大並增強全球供給能力。

關鍵成長要素包括細胞株設計技術、製程整合技術以及一次性生物反應器系統的進步，這些進步能夠提高生產產量並降低成本。對基於抗體的診斷試劑和科研試劑的需求成長也是推動收入成長的主要動力。此外，對生物相似藥和雙特異性抗體等複雜抗體形式的投資增加，正在加速產業內的創新和競爭。

展望未來，隨著抗體藥物複合體（ADC）和新一代生物製藥的商業化，市場預計將持續擴張。連續生產、模組化設施數位化品管系統將簡化作業流程並縮短產品上市時間。新興經濟體預計將在擴大產能方面發揮重要作用，而監管協調將有助於更廣泛的全球分銷。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球抗體生產市場：以抗體類型分類

• 市場分析、洞察與預測
• 單株抗體
• 多株抗體
• 其他抗體類型

第5章 全球抗體生產市場：依製程分類

• 市場分析、洞察與預測
• 上游工程
• 下游工藝
• 過濾

第6章 全球抗體生產市場：依最終用戶分類

• 市場分析、洞察與預測
• 製藥和生物技術公司
• 研究所
• 其他最終用戶

第7章 全球抗體生產市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Danaher Corporation
  • Merck KGaA
  • Sartorius
  • Thermo Fisher Scientific Inc
  • Eppendorf AG
  • INTEGRA Biosciences AG
  • Genetix Biotech Asia Pvt Ltd
  • Solaris Biotech
  • Grifols
  • F. Hoffmann-La Roche AG
  • FiberCell Systems Inc

The Antibody Production Market size is expected to reach USD 53.30 Billion in 2034 from USD 25.98 Billion (2025) growing at a CAGR of 8.31% during 2026-2034.

The Global Antibody Production market is experiencing significant growth due to the expanding pipeline of monoclonal antibodies across oncology, autoimmune diseases, and infectious disorders. Increasing regulatory approvals and biosimilar development have intensified manufacturing demand. Expansion of biologics facilities and greater outsourcing to contract development and manufacturing organizations (CDMOs) are supporting production scale-up and enhancing global supply capabilities.

Major growth drivers include advancements in cell line engineering, process intensification technologies, and single-use bioreactor systems that improve yield and reduce production costs. Rising demand for antibody-based diagnostics and research reagents further strengthens revenue generation. Additionally, increased investment in biosimilars and complex antibody formats, such as bispecific antibodies, is accelerating innovation and competitive activity within the sector.

Looking ahead, the market is poised for sustained expansion with the commercialization of antibody-drug conjugates and next-generation biologics. Continuous manufacturing, modular facilities, and digitalized quality control systems will streamline operations and reduce time-to-market. Emerging economies are expected to play a critical role in capacity expansion, while regulatory harmonization will facilitate broader global distribution.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Antibody Type

• Monoclonal Antibodies
• Polyclonal Antibodies
• Other Antibody Types

By Process

• Upstream Processing
• Downstream Processing
• Filtration

By End-user

• Pharmaceutical and Biotechnology Companies
• Research Laboratories
• Other End-users

COMPANIES PROFILED

• Danaher Corporation, Merck KGaA, Sartorius, Thermo Fisher Scientific Inc, Eppendorf AG, INTEGRA Biosciences AG, Genetix Biotech Asia Pvt Ltd, Solaris Biotech, Grifols, F HoffmannLa Roche AG, FiberCell Systems Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTIBODY PRODUCTION MARKET: BY ANTIBODY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Antibody Type
• 4.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Polyclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Other Antibody Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTIBODY PRODUCTION MARKET: BY PROCESS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Process
• 5.2. Upstream Processing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Downstream Processing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Filtration Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTIBODY PRODUCTION MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Pharmaceutical and Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Research Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Other End-users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTIBODY PRODUCTION MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Antibody Type
  • 7.2.2 By Process
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Antibody Type
  • 7.3.2 By Process
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Antibody Type
  • 7.4.2 By Process
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Antibody Type
  • 7.5.2 By Process
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Antibody Type
  • 7.6.2 By Process
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ANTIBODY PRODUCTION INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Danaher Corporation
  • 9.2.2 Merck KGaA
  • 9.2.3 Sartorius
  • 9.2.4 Thermo Fisher Scientific Inc
  • 9.2.5 Eppendorf AG
  • 9.2.6 INTEGRA Biosciences AG
  • 9.2.7 Genetix Biotech Asia Pvt Ltd
  • 9.2.8 Solaris Biotech
  • 9.2.9 Grifols
  • 9.2.10 F. Hoffmann-La Roche AG
  • 9.2.11 FiberCell Systems Inc